Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Breast Cancer Res Treat. 2020 Jun;181(2):347-359. doi: 10.1007/s10549-020-05622-5. Epub 2020 Apr 9.

Abstract

Purpose: Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials.

Methods: A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years.

Results: Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point.

Conclusion: Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.

Keywords: Breast cancer; Depression; Endocrine treatment; Sexual problems; Treatment-induced symptoms.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / psychology
  • Chemotherapy, Adjuvant / adverse effects*
  • Depressive Disorder / chemically induced
  • Depressive Disorder / epidemiology*
  • Depressive Disorder / pathology
  • Female
  • Follow-Up Studies
  • Global Health
  • Humans
  • Incidence
  • International Agencies
  • Middle Aged
  • Premenopause
  • Prognosis
  • Quality of Life
  • Sexual Dysfunction, Physiological / etiology*
  • Sexual Dysfunction, Physiological / pathology
  • Sleep Wake Disorders / chemically induced
  • Sleep Wake Disorders / epidemiology*
  • Sleep Wake Disorders / pathology
  • Tamoxifen / adverse effects*

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen